Metformin, a first-line biguanide, reduces hepatic glucose production, while tirzepatidea dual GIP/GLP-1 receptor agonist approved by the FDA in 2022enhances insulin secretion, suppresses glucagon, and promotes weight loss
Obesity 27 , 20052010 (2019)
While the numbers we estimate are for Great Britain as a whole, it is noteworthy that the number using these medications for weight loss far exceeds the initial expectation for NHS England to provide treatment for 220,000 people in the first 3 years, which is likely to have important consequences for NHS budgets, although our estimate is less than the number eligible according to NICE guidelines (3.4 million) [14]
Some peptides like GH secretagogues may enhance sleep quality
Compounded semaglutide from a vial allows physicians to prescribe intermediate doses like 0.75mg or 1.25mg, which can help patients who experience side effects at standard dose jumps